Abstract 2529
Background
Compared with quantification of messenger RNA, a protein level quantification allows for more relevant clinical outcome predictions and the identification of potential therapeutic targets. The aim of this study was to identify a novel protein level signature that was associated with overall survival in patients with resected pancreatic ductal adenocarcinoma (PDAC).
Methods
Data of 105 patients with resected PDAC were retrieved from TRGAted. Reverse-phase protein array (RPPA) quantification data of 218 proteins were collected. By using the LASSO regression model, a protein-level-based classifier was built. Time-dependent receiver operating characteristic (ROC) analysis was used to assess the prognostic accuracy of the classifier. Survival curves were compared by using the Kaplan-Meier analysis.
Results
Using the LASSO model, we built a classifier based on four proteins: BAK, IGFBP2, PDL1, and BRAF-pS445. Survival analysis revealed IGFBP2 and BRAF-pS445 were two favourable prognostic markers, and BAK and PDL1 were unfavourable prognostic markers. Using the classifier, we were able to classify patients between those at high risk of disease progression (high-risk group) and those at low risk of disease progression (low-risk group). Progression-free survival was significantly different between these two groups (11.7 vs 19.9 months for high-risk and low-risk groups, respectively; P < 0.0001). The median overall survival was 13.1 and 36.7 months for the high-risk and low-risk groups, respectively (hazard ratio [HR]: 4.09; 95% CI: 2.39 - 6.98; P < 0.0001). Five-year survival rate was 0% for the high-risk group, and 46% for the low-risk group. The prognostic accuracy (area under the ROC curve) of the classifier were 0.75, 0.77, and 0.81 at 1, 3, and 5 years, respectively. Multivariate Cox regression analysis showed that the classifier was an independent prognostic factor (P < 0.0001).
Conclusions
This protein-level classifier is a novel prognostic tool in patients with resected PDAC. It may facilitate individualized management of patients with this disease.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Jie Hua.
Funding
The National Science Fund for Distinguished Young Scholars of China (grant number 81625016).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
3516 - Palbociclib Rechallenge in Hormone Receptor (HR)[+]/HER2[-] Advanced Breast Cancer (ABC). PALMIRA Trial
Presenter: Antonio Llombart Cussac
Session: Poster Display session 2
Resources:
Abstract
4616 - Alpelisib (ALP) + Endocrine Therapy (ET) by Last Prior Therapy in Patients (pts) With PIK3CA-Mutated Hormone-Receptor Positive (HR+) Human Epidermal Growth Factor Receptor-2-Negative (HER2–) Advanced Breast Cancer (ABC): Additional Study Cohort in BYLieve
Presenter: Eva Ciruelos
Session: Poster Display session 2
Resources:
Abstract
3592 - PRECYCLE: Impact of CANKADO-based eHealth-support on quality of life in metastatic breast cancer patients treated with palbociclib and endocrine therapy.
Presenter: Tom Degenhardt
Session: Poster Display session 2
Resources:
Abstract
4168 - Efficacy and safety of oral poly (ADP-ribose) polymerase inhibitor fluzoparib in patients with BRCA1/2 mutations and platinum sensitive recurrent ovarian cancer
Presenter: Ning Li
Session: Poster Display session 2
Resources:
Abstract
2785 - Effect of response to last platinum-based chemotherapy in patients (pts) with platinum-sensitive, recurrent ovarian carcinoma in the phase 3 study ARIEL3 of rucaparib maintenance treatment
Presenter: Jonathan Ledermann
Session: Poster Display session 2
Resources:
Abstract
3496 - Integrated safety analysis of the poly(ADP-ribose) polymerase (PARP) inhibitor rucaparib in patients (pts) with ovarian cancer in the treatment and maintenance settings
Presenter: Rebecca Kristeleit
Session: Poster Display session 2
Resources:
Abstract
2844 - Clinical factors associated with prolonged response and survival under olaparib as maintenance therapy in BRCA mutated ovarian cancers
Presenter: S.Intidhar Labidi-Galy
Session: Poster Display session 2
Resources:
Abstract
1955 - A Prospective Evaluation of Tolerability of Niraparib Dosing Based on Baseline Body Weight (BW) and Platelet (plt) Count: Blinded Pooled Interim Safety Data from the NORA Study
Presenter: Xiaohua Wu
Session: Poster Display session 2
Resources:
Abstract
2539 - Evaluation of Niraparib 200 mg/d as Maintenance Therapy in Recurrent Ovarian Cancer and Associated Thrombocytopenia in a Real-World US Setting
Presenter: Premal Thaker
Session: Poster Display session 2
Resources:
Abstract
1290 - Niraparib initial dose and its’ management in patients with recurrent high-grade serous ovarian cancer.
Presenter: Jacek Grabowski
Session: Poster Display session 2
Resources:
Abstract